Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 2, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,455,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,553 pence per share; lowest price paid was 1,537 pence per share.
- Treasury Holdings (Settled): 482,764,412 shares (9.00% of total issued share capital).
- Treasury Holdings (Including Unsettled): 487,264,412 shares (9.98% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,882,908,956 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,455,000 shares for Treasury. Consequently, the Company's Treasury holdings now represent 9.00% of total issued share capital and 9.98% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,882,908,956) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (482,764,412 settled) for assessing dilution or buyback program progress.
- Note that the 9.98% voting rights figure includes shares purchased but not yet settled.